Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535261 | 0.87 | HDAC6 (1.00) | HDAC6HDAC11HDAC8HDAC5HDAC4 | |
| SCHEMBL20535890 | 0.86 | HDAC6 (1.00) | HDAC6HDAC11HDAC8HDAC5HDAC4 | |
| SCHEMBL20535308 | 0.86 | HDAC6 (0.75) | HDAC6HDAC11HDAC8HDAC5HDAC3 | |
| SCHEMBL20534929 | 0.86 | HDAC6 (1.00) | HDAC6HDAC11HDAC8HDAC5HDAC4 | |
| SCHEMBL20535208 | 0.83 | HDAC6 (1.00) | HDAC6HDAC11HDAC8HDAC5HDAC4 | |
| SCHEMBL20535185 | 0.80 | HDAC6 (1.00) | HDAC6HDAC11HDAC8HDAC4HDAC7 | |
| SCHEMBL21712147 | 0.75 | HDAC6 (0.75) | HDAC6HDAC11HDAC8HDAC5HDAC3 | |
| SCHEMBL20535205 | 0.75 | HDAC6 (1.00) | HDAC6HDAC11HDAC8HDAC5HDAC4 | |
| SCHEMBL19321961 | 0.75 | P2RX7 (0.63) | HDAC6HDAC11HDAC8MEN1KMT2A | |
| SCHEMBL2406724 | 0.74 | HDAC6 (0.59) | HDAC6HDAC11HDAC8HDAC5HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472271-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4397656-A2 | HDAC6 INHIBITORS AND IMAGING AGENTS | The General Hospital Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240148915-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2024-05-09 | — | — | US | disclosed |
| EP-3609864-B1 | HDAC6 INHIBITORS AND IMAGING AGENTS | MASSACHUSETTS GEN HOSPITAL (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11890356-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11207431-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-11207431-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200054773-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2020-02-20 | — | — | US | disclosed |
| US-20200054773-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2020-02-20 | — | — | US | disclosed |
| EP-3609864-A1 | HDAC6 INHIBITORS AND IMAGING AGENTS | The General Hospital Corporation (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191360-A1 | HDAC6 INHIBITORS AND IMAGING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054773-A1 | HDAC6 Inhibitors and Imaging Agents | HDAC1, HDAC6, HDAC11 | HDAC6 2/4885HDAC11 3/4885HDAC8 5/4885 |
| US-11207431-B2 | HDAC6 inhibitors and imaging agents | HDAC1, HDAC6, HDAC11 | HDAC6 2/4885HDAC11 3/4885HDAC8 5/4885 |
| US-20240148915-A1 | HDAC6 Inhibitors and Imaging Agents | HDAC1, HDAC6, HDAC11 | HDAC6 2/4885HDAC11 3/4885HDAC8 5/4885 |
| US-12472271-B2 | HDAC6 inhibitors and imaging agents | HDAC1, HDAC6, HDAC11 | HDAC6 2/4885HDAC11 3/4885HDAC8 5/4885 |
| US-11890356-B2 | HDAC6 inhibitors and imaging agents | HDAC1, HDAC6, HDAC11 | HDAC6 2/4885HDAC11 3/4885HDAC8 5/4885 |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | HDAC1, HDAC6, HDAC11 | HDAC6 2/4885HDAC11 3/4885HDAC8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.